CAPRI-3 Study: A phase 3 clinical trial to evaluate the use of continuous cetuximab treatment beyond first-line progression in patients with molecularly selected metastatic colorectal cancer.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: GRUPPO ONCOLOGICO DELL'ITALIAMERIDIONALE, GOIM
- Phase: III
- Execution start: 21/10/2025
- End of execution: 30/06/2030
- IP: ENCARNA GONZALEZ FLORES
